Results 11 to 20 of about 1,630,140 (194)

Therapeutic apheresis in autoimmune diseases

Open Access Rheumatology: Research and Reviews, 2013
Rolf Bambauer,1 Reinhard Latza,2 Carolin Bambauer,3 Daniel Burgard,4 Ralf Schiel5 1Institute for Blood Purification, Homburg, 2Laboratorium of Medicine, St Ingbert, 3Main Hospital Darmstadt, Darmstadt, 4Herz Zentrum, Cardiology, Völklingen ...
Bambauer R, Latza R, Bambauer C, Burgard D, Schiel R   +4 more
doaj   +1 more source

International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report [PDF]

, 2023
Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases.
Serdal Korkmaz, Fadime Ersoy Dursun, Cagliyan, Gulsum Akgun, Uysal, Ayşe, Sinan Demircioglu, Dal, Mehmet Sinan, Vahap Okan, Didar Yanardag Acik, Ekinci, Omer, Duzgun Ozatli, Tugce Nur Yigenoglu, Basturk, Abdulkadir, Abdulkadir Basturk, Mehmet Ali Erkurt, Yigenoglu, Tugce Nur, Aslı Odabaşı Giden, Mahmut Yeral, Kartı, Sami, Mehmet Sinan Dal, Sami Kartı, Bulent Eser, Omer Ekinci, Osman Yokus, Aydan Akdeniz, Okan, Vahap, Dursun, Fadime Ersoy, Burhan Turgut, Hacioglu, Sibel Kabukcu, Bilen, Yusuf, Gul Ilhan, Ozatli, Duzgun, Ayşe Uysal, Aydogdu, Ismet, Eser, Bulent, Serefhanoglu, Songül, Rafiye Ciftciler, Abdullah Karakus, Mustafa Merter, Sibel Kabukcu Hacioglu, Fevzi Altuntas, Kuku, Irfan, Hacibekiroglu, Tuba, Altuntas, Fevzi, Umit, Elif Gulsum, Gulsum Akgun Cagliyan, Albayrak, Murat, Semih Basci, Ozet, Gulsum, Mehmet Sonmez, Demircioglu, Sinan, Akdeniz, Aydan, Cengiz Demir, Giden, Aslı Odabaşı, Ilhan, Gul, Irfan Kuku, Elif Gulsum Umit, Yusuf Bilen, Ozkurt, Zubeyde Nur, Sincan, Gulden, Acik, Didar Yanardag, Demir, Cengiz, Murat Kacmaz, Hindilerden, Fehmi, Zubeyde Nur Ozkurt, Sinem Namdaroglu, Turgut, Burhan, Yokus, Osman, Mehmet Ali Ucar, Seckin Cagirgan, Yeral, Mahmut, Tuba Hacibekiroglu, Ciftciler, Rafiye, Gulsum Ozet, Ucar, Mehmet Ali, Teke, Hava Uskudar, Gulden Sincan, Korkmaz, Serdal, Sonmez, Mehmet, Turgay Ulas, Atakan Tekinalp, Cagirgan, Seckin, Hava Uskudar Teke, Kacmaz, Murat, Ismet Aydogdu, Merter, Mustafa, Murat Albayrak, Tekinalp, Atakan, Songül Serefhanoglu, Fehmi Hindilerden, Ozkurt Z.N., Kuku I., Akdeniz A., Hindilerden F., Uysal A., Giden, Asli Odabasi, Hacioglu S.K., Giden A.O., Başçı, S., Ucar M.A., Ciftciler R., Özatlı, D., Erkurt, Mehmet Ali, Turgut B., Erkurt, M.A., Sincan G., Basci, Semih, Ulaş, Turgay, Teke, HAVA, Başçı, Semih, Özatlı, Düzgün, Tekinalp A., Kartı S., Ilhan G., Korkmaz, S., Korkmaz S., Ekinci O., Cagirgan S., Eser B., Giden, A.O., Basturk A., Karakuş, Abdullah, Bilen Y., Ozatli D., Demir C., Karakus A., Cagliyan G.A., Kacmaz M., Altuntas F., Namdaroglu S., Dursun F.E., Yigenoglu T.N., Ozet G., Erkurt M.A., Turgut, B., Serefhanoglu S., Ulaş, T., Merter M., Dal M.S., Yeral M., Acik D.Y., Albayrak M., Okan V., Aydogdu I., Hacibekiroglu T., Basci S., Demircioglu S., Umit E.G., Yokus O., Namdaroglu, Sinem, Sonmez M., Teke H.U., Ulas T.   +151 more
core   +2 more sources

Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis. [PDF]

J Clin Apher
Dual specialty ports were evaluated for safety and efficacy in therapeutic apheresis by analyzing outcomes across 97 port placement events in 88 patients, focusing on two configurations: dual Bard PowerFlow (BP2) and a combination of Bard PowerFlow with ...
Swar-Eldahab M, Obeng-Gyasi B, Haste P, Krosin M.   +3 more
europepmc   +2 more sources

The scientific basis and future of lipoprotein apheresis [PDF]

, 2021
Lipoprotein apheresis plays a vital role in the management of the severe hyperlipidemias that predispose to atherosclerosis. Determinants of efficacy are the acute reduction in lipoproteins achieved by each apheresis procedure, their frequency, and the ...
Gilbert R. Thompson, Thompson, Gilbert R
core   +1 more source

The Place of Therapeutic Apheresis in Severe Immune-Related Adverse Events: A Scoping Review of Literature. [PDF]

J Clin Apher
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
Vuillet C, Moranne O, Daubin D, Quantin X, Palassin P, Kanouni T, Maria ATJ, MonRIO network (Montpellier Réseau Immuno‐Oncologie).   +7 more
europepmc   +2 more sources

Apheresis in developing countries around the world

, 2021
At the combined American Society for Apheresis (ASFA) Annual Meeting/World Apheresis Association (WAA) Congress in San Francisco, California, in April of 2014, the opening session highlighted the status of apheresis outside of the United States.
Marques Jr., José Francisco Comenalli, Eichbaum, Quentin, Naim, Norris, Mendrone Jr., Alfredo, Crookes, Robert, Smid, W. Martin, Marques, Marisa B.   +6 more
core   +2 more sources

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Turkish Journal of Hematology, 2020
Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is considered as a chronic life-long disease, which could be manageable with tyrosine kinase inhibitor (TKI) drugs.
İbrahim C. Haznedaroğlu, Işınsu Kuzu, Osman İlhan   +2 more
doaj   +1 more source

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

World Allergy Organization Journal, 2021
Immunoglobulin E (IgE) plays an essential role in many allergic diseases. This review highlights the role of IgE in atopic dermatitis (AD), a common, chronic, and complex skin inflammation, and the available therapeutic approaches that target IgE in AD ...
Andreas Wollenberg, Simon Francis Thomsen, Jean-Philippe Lacour, Xavier Jaumont, Slawomir Lazarewicz   +4 more
doaj   +1 more source

Evaluation of hierarchical teaching model in advanced training of therapeutic blood component apheresis

Zhongguo shuxue zazhi, 2023
Objective To explore the efficiency of hierarchical teaching model in advanced training of therapeutic blood component apheresis. Methods A total of 76 students who participated in the advanced training(≥3 months) of therapeutic blood component apheresis
Can ZHU, Zhongjun LI
doaj   +1 more source

Study on the production efficiency of platelet components in 24 prefecture-level blood stations in China

Zhongguo shuxue zazhi, 2022
Objective To learn the production efficient of platelet components among prefecture-level blood stations in China, to provide supporting data for those blood stations to optimize the production mode of platelet components and continuously improve ...
Minyu HUA, Wei NIU, Jian YAO, Shouguang XU, Yuxia QIU, Li LI, Dongmei ZHAO, JiaYu WAN, Feng YAN, Hongzhi JIA, Hao LI, Jiaqi QiIAN, Peng WANG, Zhenxing WANG, Lin BAO, Shan WEN, Sheng YE, Xuefang FENG, Man ZHANG, Xiaobo CAI, Wei Zhang, Dexu CHU, Youhua SHEN, Peifang CONG, Hui ZHANG, Yan QIU   +25 more
doaj   +1 more source